Order SND/1053/2026 provides the annual update to the drug reference pricing system within the National Health System. The regulation establishes new groups of medicines, revises prices for existing groups, and removes those that no longer meet legal requirements (Art. 5.1 RD 177/2014). This update serves as a pharmaceutical expenditure control tool to ensure the sustainability of the public healthcare system.
For pharmaceutical laboratories and manufacturers, the regulation necessitates a review of margins and selling prices, as new reference prices are set and existing ones are updated (Order SND/1053/2026). Pharmacies and the National Health System will see adjustments in financing and dispensing costs based on the newly approved groups and prices. Affected parties have one month to file an administrative appeal (recurso de reposición) or two months to initiate contentious-administrative proceedings before the National Court (Audiencia Nacional).
The administrative team reviews your specific situation.
What is published here, applied to a company or a specific case. The first meeting is free.